Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators

[1]  E. Rossin,et al.  Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy , 2020, Scientific Reports.

[2]  V. Cottin,et al.  Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease , 2020, American journal of respiratory and critical care medicine.

[3]  J. Bushweller,et al.  TNF‐α signaling regulates RUNX1 function in endothelial cells , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Wenying Lu,et al.  Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? , 2020, European Respiratory Journal.

[5]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[6]  Ademola S. Ojo,et al.  Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies , 2020, Pulmonary medicine.

[7]  N. Rezaei,et al.  Immunotherapy for SARS-CoV-2: potential opportunities , 2020, Expert Opinion on Biological Therapy.

[8]  Liming Xu,et al.  LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1 , 2020, Cell Death & Disease.

[9]  P. Gibson,et al.  COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS , 2020, The Medical journal of Australia.

[10]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[11]  J. van Paassen,et al.  A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression , 2020, Modern Pathology.

[12]  I. Solomon,et al.  In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19 , 2020, Modern Pathology.

[13]  M. Humbert,et al.  Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? , 2020, European Respiratory Journal.

[14]  M. Aepfelbacher,et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.

[15]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[16]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[17]  T. Uyeki,et al.  Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States , 2020, Emerging infectious diseases.

[18]  A. Wells,et al.  Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy , 2020, The Lancet Respiratory Medicine.

[19]  G. Glinsky.  Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells , 2020, Biomedicines.

[20]  G. Wertheim,et al.  Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling. , 2020, Blood advances.

[21]  Jianping Zhao,et al.  Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-analysis. , 2019, Chest.

[22]  A. Regev,et al.  Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers , 2019, Proceedings of the National Academy of Sciences.

[23]  Xiaodong Han,et al.  M2 macrophages promote myofibroblast differentiation of LR-MSCs and are associated with pulmonary fibrogenesis , 2018, Cell Communication and Signaling.

[24]  Joyce S Lee,et al.  Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives , 2018, Patient related outcome measures.

[25]  D. Lederer,et al.  Idiopathic Pulmonary Fibrosis. , 2018, The New England journal of medicine.

[26]  W. Cai,et al.  Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ , 2018, EBioMedicine.

[27]  Peter Chen,et al.  Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis , 2018, Cell reports.

[28]  L. Ware,et al.  Selective tumour necrosis factor receptor-1 inhibition in acute lung injury: a new hope or a false dawn? , 2018, Thorax.

[29]  M. Kreuter,et al.  Nintedanib with Add‐on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial , 2017, American journal of respiratory and critical care medicine.

[30]  Xiaohua Yan,et al.  Feedback regulation of TGF-β signaling. , 2018, Acta biochimica et biophysica Sinica.

[31]  F. Luo,et al.  Runt‐Related Transcription Factor 1 Regulates LPS‐Induced Acute Lung Injury via NF‐&kgr;B Signaling , 2017, American journal of respiratory cell and molecular biology.

[32]  V. Aidinis,et al.  Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis , 2017, Front. Med..

[33]  D. Laskin,et al.  Anti‐TNF&agr; therapy in inflammatory lung diseases , 2017, Pharmacology & therapeutics.

[34]  Lishuang Shen,et al.  Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis , 2017, Diabetes.

[35]  N. Speck,et al.  The Role of Runx1 in Embryonic Blood Cell Formation. , 2017, Advances in experimental medicine and biology.

[36]  Mazhar Adli,et al.  Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers , 2016, EBioMedicine.

[37]  N. Frangogiannis.  Fibroblast—Extracellular Matrix Interactions in Tissue Fibrosis , 2016, Current Pathobiology Reports.

[38]  D. Laskin,et al.  Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-α Antibody. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  R. Hubbard,et al.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review , 2015, European Respiratory Journal.

[40]  K. Chan,et al.  RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation , 2014, Proceedings of the National Academy of Sciences.

[41]  S. Gharib,et al.  MMP28 promotes macrophage polarization toward M2 cells and augments pulmonary fibrosis , 2014, Journal of leukocyte biology.

[42]  Jun-Sub Choi,et al.  TGF-β1 regulates cell fate during epithelial–mesenchymal transition by upregulating survivin , 2013, Cell Death and Disease.

[43]  T. Maher.  PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery , 2013, European Respiratory Review.

[44]  W. Reinhold,et al.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction , 2012, Proceedings of the National Academy of Sciences.

[45]  C. Barber,et al.  Importance of past occupational exposures in the rising incidence of idiopathic pulmonary fibrosis in the UK , 2011, Thorax.

[46]  M. Selman,et al.  Idiopathic pulmonary fi brosis , 2011 .

[47]  J. Lasky,et al.  TGF-β: Titan of Lung Fibrogenesis. , 2010, Current enzyme inhibition.

[48]  Christopher C W Hughes,et al.  TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. , 2008, Blood.

[49]  T. Mukherjee,et al.  Role of TNFα in pulmonary pathophysiology , 2006, Respiratory Research.

[50]  A. Roberts,et al.  Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-β-Mediated Pulmonary Fibrosis1 , 2004, The Journal of Immunology.

[51]  Rakesh K. Kumar.  Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder , 2002, Respiratory Research.

[52]  G. Thomas,et al.  Furin at the cutting edge: From protein traffic to embryogenesis and disease , 2002, Nature Reviews Molecular Cell Biology.

[53]  Jerónimo Bravo,et al.  The leukemia-associated AML1 (Runx1)–CBFβ complex functions as a DNA-induced molecular clamp , 2001, Nature Structural Biology.

[54]  I. Lossos,et al.  Human Recombinant Interferon-α2a and Interferon-αA/D Have Different Effects on Bleomycin-Induced Lung Injury , 2001, Respiration.

[55]  N. Seidah,et al.  Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. , 2001, The American journal of pathology.

[56]  I. Lossos,et al.  Human recombinant interferon-alpha2a and interferon-alphaA/D have different effects on bleomycin-induced lung injury. , 2001, Respiration; international review of thoracic diseases.

[57]  I. Lossos,et al.  Effect of Immunomodulators on Bleomycin-Induced Lung Injury , 1999, Respiration.

[58]  Xing Shen,et al.  Smads bind directly to the Jun family of AP-1 transcription factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  I. Lossos,et al.  The effect of enoxaparin on bleomycin-induced lung injury in mice. , 1999, Experimental lung research.

[60]  C. Pettinelli,et al.  A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. , 1995, The Journal of infectious diseases.

[61]  A. Schutt,et al.  Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Lazo,et al.  Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. , 1988, The Journal of pharmacology and experimental therapeutics.

[63]  W. Risau,et al.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. , 1987, Proceedings of the National Academy of Sciences of the United States of America.